Facet Joint and Medial Branch Block Injections for Spinal Pain
This policy governs medical necessity and coverage criteria for diagnostic and therapeutic facet joint injections and medial branch blocks for spinal pain under UnitedHealthcare Commercial and Individual Exchange plans.
Policy Summary
PayerUnitedHealthcare
PolicyFacet Joint and Medial Branch Block Injections for Spinal Pain
Policy CodePolicy 2026T0004VV
Change TypeRevised clinical evidence, description of services, and references
Effective DateMay 1, 2026
Next Review Date
Key ActionObtain prior authorization and document diagnostic strategy, percent pain relief, and prior conservative therapy before requesting coverage.
Updated Description of Services, Clinical Evidence, and References sections to reflect the most current information.
>=50%pain relief threshold to consider diagnostic block positive
80% reliefdiagnostic improvement threshold cited by societies
4 weeksminimum conservative care before diagnostic injection
0.5 mLmax local anesthetic volume for medial branch blocks
05/01/2026
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.
policy revision date (summary)
Coverage Criteria for Facet Joint and Medial Branch Injections
Initial diagnostic injection criteria: Pain is exacerbated by facet loading maneuvers on physical examination (e.g., hyperextension, rotation); and clinically significant improvement has not occurred (pain >=3/10) after a minimum of 4 weeks of conservative care (including but not limited to pharmacotherapy, exercise, or physical therapy); and clinical findings and imaging studies suggest no other cause of the pain (e.g., spinal stenosis with neurogenic claudication, disc herniation with radicular pain, infection, tumor, fracture, pain related to prior surgery); and the spinal motion segment is not fused; and a radiofrequency joint denervation/ablation procedure is being considered
Second (confirmatory) Diagnostic Injection
Covered when ALL of the following are met
Second confirmatory diagnostic injection criteria: Administered at the same level and side as the initial block; and the initial diagnostic Facet Joint Injection produced a positive response for at least the expected minimum duration of the effect of the local anesthetic; and functional improvement that is specific to the individual, with demonstrable improvement in the physical functions previously limited by the facetogenic pain; and a radiofrequency joint denervation/ablation procedure is being considered
Second block is to confirm validity of initial positive response
Diagnostic and preprocedural criteria
Covered when ALL of the following are met
Diagnostic confirmation: Dual diagnostic medial branch blocks performed in the same location(s) on two separate occasions are used to confirm facet joint pain due to high false-positive rates of single injections; a second confirmatory injection is indicated only if the first injection produces >= 80% relief and the onset and minimum duration of relief is consistent with the agent used.>= 80% relief for confirmatory block
Second confirmatory injection indicated only if first produced >=80% relief or if different level suspected
Conservative therapy: Conservative management trial prior to prognostic/therapeutic blocks: at least a 6-week to 3-month trial of noninvasive treatments (medications, physical therapy, integrative modalities) per society guidance; lumbar guidance often cites 3 months while cervical guidance may cite 6 weeks.6-12 weeks or up to 3 months
ASRA/ASIPP/other society guidance recommends conservative trials before interventions
Therapeutic injection considerations
Therapeutic injections considered when ALL of the following are met (reflecting limited/variable evidence and society recommendations)
Documentation of prior diagnostic confirmation: Therapeutic intra-articular or medial branch steroid/local anesthetic injections should be preceded by appropriate diagnostic confirmation of facet-mediated pain (per diagnostic criteria above).diagnostic confirmation documented
Societies caution limited routine use of therapeutic injections
Evidence of benefit: Evidence for therapeutic benefit is variable and generally low quality: some reviews report short-term benefit (often 1–3 months) but studies are downgraded for bias, inconsistency, and imprecision; intra-articular steroid injections show highly uncertain effectiveness in systematic reviews.clinical improvement often short-term (1-6 months)
Multiple systematic reviews and evidence assessments call for higher-quality randomized placebo-controlled trials
Patient selection caveats:
Guidance modality and imaging
Imaging/guidance considerations
Ultrasound vs fluoroscopy/CT: No high-quality evidence demonstrates overall health benefit of ultrasound guidance over fluoroscopy or CT for spinal facet injections; ultrasound is operator dependent, may reduce radiation exposure and procedure time but has reported higher risk of incorrect needle placement (11–13% risk difference) when verified by fluoroscopy/CT.operator-dependent accuracy concerns
Clinical guidelines do not recommend ultrasound-guided facet injections as standard of care; training/experience required
Diagnostic medial branch block criteria
Covered when ALL of the following are met (diagnostic medial branch blocks):
Dual diagnostic blocks required: Dual medial branch blocks performed in the same location(s) on two separate occasions are necessary to confirm the diagnosis due to high false-positive rate of single injections.two separate occasions
Based on society recommendations (NASS/ASIPP/ASRA)
Criteria for second confirmatory injection: A second confirmatory injection is indicated only if the first injection produces >= 80% relief of the primary (index) pain and the onset and minimum duration of relief is consistent with the agent used; this confirmatory block establishes the tested joint as the pain source.>= 80% relief
NASS/other society guidance
When to repeat at different level: A second injection may be performed at a different or additional level if the pain is believed to arise from a different joint and the relief from the initial block was < 80%.
Therapeutic interventions - evidence and limitations
Therapeutic use and evidence stance:
Therapeutic medial branch blocks are performed similarly to diagnostic blocks and intended for long-term pain management, but current evidence does not support their use as a therapeutic intervention.
NASS statement: insufficient evidence
Intra-articular steroid injections: In patients selected using physical exam and a single diagnostic intra-articular injection with 50% relief, intra-articular steroid injection provides no clinically meaningful improvement at 6 months (Grade B); overall evidence for therapeutic intra-articular injections is low or insufficient for firm recommendations (Grade I statements).50% relief used in referenced studies
NASS evidence grades
Therapeutic facet joint and medial branch block injections performed after diagnostic injections are considered unproven and not medically necessary when radiofrequency ablation is not being considered, when used to treat spinal pain after diagnostic injections, or when performed after two injections at the same level and side (these circumstances are considered therapeutic rather than diagnostic). Requests in these scenarios may be denied as they lack sufficient evidence of efficacy and safety. Medial branch blocks with local anesthetic volumes >0.5 mL and procedures performed under ultrasound guidance are also considered unproven and not medically necessary.
Therapeutic facet joint/medial branch injections at the cervical, thoracic, and lumbar spine levels are judged unproven and not medically necessary due to insufficient and low-quality evidence regarding clinical benefit and safety.
Clinical guidance and society statements advise that the routine use of therapeutic facet joint injections is not recommended for acute or subacute low back pain, for radicular pain syndromes, or as routine treatment of chronic nonspecific axial pain. ACOEM specifically lists these indications as not recommended, and ASRA and VA/DoD guidance discourage routine corticosteroid use for intra-articular and therapeutic medial branch injections.
Systematic reviews and technology assessments report variable, generally low-quality evidence for therapeutic facet injections with short- to mid-term benefit reported in some studies (commonly 1–6 months) but important limitations including risk of bias, heterogeneity, and few placebo-controlled trials. These factors support conservative, selective use rather than routine application.
There is no published literature addressing intra-articular facet joint injections for thoracic pain; NASS advises clinicians to weigh risks and benefits carefully and to compare these interventions with other palliative care options when managing thoracic spine pain. Available studies for thoracic procedures are limited and clinicians should consider the limited evidence base when recommending intra-articular injections in the thoracic region.
Because evidence is limited to retrospective series or case reports for thoracic facet interventions, individualized clinical judgment and discussion of alternatives and uncertainties with the patient are recommended.
Therapeutic facet joint and medial branch injections at cervical, thoracic, and lumbar levels are considered unproven and not medically necessary because systematic reviews and guideline statements identify insufficient, low-quality, and inconsistent evidence for durable clinical benefit. Multiple reviews downgrade evidence for bias, indirectness, inconsistency, and imprecision, and sham-controlled trials have failed to show consistent efficacy.
Given these evidence limitations, therapeutic injections should not routinely replace evidence-based alternatives such as radiofrequency denervation when appropriate, and requests for therapeutic injections without appropriate diagnostic confirmation or when radiofrequency ablation is not being considered may be denied.
Therapeutic facet joint injections generally lack high-quality evidence demonstrating consistent long-term efficacy; systematic reviews report wide variability in pain and functional outcomes and often downgrade the quality of evidence due to methodological limitations. ACOEM, ASRA, and VA/DoD guidance specifically discourage routine use of intra-articular corticosteroids and therapeutic medial branch injections in many scenarios.
Where short-term improvement is observed in some studies (commonly up to 3–6 months), the clinical significance and durability remain uncertain. For these reasons, therapeutic facet injections should be reserved for select patients after diagnostic confirmation and consideration of alternatives.
Therapeutic medial branch blocks—administered like diagnostic blocks but intended for long-term pain control—are not supported by current evidence as a therapeutic intervention; NASS and other reviews conclude evidence does not demonstrate consistent benefit. Intra-articular steroid injections, when selected using a single diagnostic injection with ≥50% relief, have not shown clinically meaningful improvement at 6 months in several analyses (NASS Grade B for that statement), and many recommendations remain Grade I (insufficient evidence).
Consequently, therapeutic medial branch blocks and intra-articular steroid injections should not be used routinely for long-term management without documented diagnostic confirmation and clear, individualized rationale.
Conservative Treatment and Prerequisites
Documented trial of conservative therapy with persistent pain (>=3/10)
Covered when ALL of the following are met
Conservative therapy documented: Documented trial of conservative therapy (pharmacotherapy, exercise, or physical therapy) for a minimum of 4 weeks with persistent pain rated >= 3/10 prior to initial diagnostic injection.minimum 4 weeks
Medical records should document therapies attempted and persistent pain level
Document trial of conservative measures prior to prognostic/therapeutic facet interventions.
Covered when ALL of the following are met
Conservative measures prior to prognostic/therapeutic blocks: Documented trial of conservative measures prior to prognostic or therapeutic facet interventions: at least 6 weeks to 3 months of noninvasive treatments (medications, physical treatments, integrative therapies), with duration adapted by spinal level and guideline recommendations.
Frequency and Repeat Procedure Guidance
inv-40: Diagnostic facet joint/medial branch blocks — Second diagnostic block may be performed to confirm response; therapeutic injections after two diagnostic blocks are considered therapeut...
SummarySecond diagnostic (confirmatory) facet joint/medial branch block may be performed to confirm the validity of the clinical response to the initial diagnostic injection when administered at the same level and side and the initial injection produced a positive response for at least the expected minimum duration of the local anesthetic.
When indicatedAdministered at the same level and side as the initial block to confirm the prior positive response.
Required prior responseInitial diagnostic injection must have produced a positive response (see diagnostic positive threshold) for at least the expected minimum duration of the anesthetic.
PurposeConfirm that the tested joint/medial branch is the pain generator prior to consideration of radiofrequency denervation/ablation.
Not indicatedA second block is not appropriate if the initial injection did not confirm the joint as the source of pain (i.e., no adequate positive response).
Applicable Procedure and Diagnosis Codes
Applicable Procedure CodesCPT
0213T
Injection(s), diagnostic or therapeutic agent, paravertebral facet (zygapophyseal) joint with ultrasound guidance, cervical or thoracic; single level.
0214T
Injection(s), diagnostic or therapeutic agent, paravertebral facet (zygapophyseal) joint with ultrasound guidance, cervical or thoracic; second level (List separately in addition to code for primary procedure).
0215T
Injection(s), diagnostic or therapeutic agent, paravertebral facet (zygapophyseal) joint with ultrasound guidance, cervical or thoracic; third and any additional level(s) (List separately in addition to code for primary procedure).
0216T
Injection(s), diagnostic or therapeutic agent, paravertebral facet (zygapophyseal) joint with ultrasound guidance, lumbar or sacral; single level.
0217T
Injection(s), diagnostic or therapeutic agent, paravertebral facet (zygapophyseal) joint with ultrasound guidance, lumbar or sacral; second level (List separately in addition to code for primary procedure).
0218T
Injection(s), diagnostic or therapeutic agent, paravertebral facet (zygapophyseal) joint with ultrasound guidance, lumbar or sacral; third and any additional level(s) (List separately in addition to code for primary procedure).
64490
Injection(s), diagnostic or therapeutic agent, paravertebral facet (zygapophyseal) joint with image guidance (fluoroscopy or CT), cervical or thoracic; single level.
64491
Injection(s), diagnostic or therapeutic agent, paravertebral facet (zygapophyseal) joint with image guidance (fluoroscopy or CT), cervical or thoracic; second level (List separately in addition to code for primary procedure).
64492
Injection(s), diagnostic or therapeutic agent, paravertebral facet (zygapophyseal) joint with image guidance (fluoroscopy or CT), cervical or thoracic; third and any additional level(s) (List separately in addition to code for primary procedure).
64493
Injection(s), diagnostic or therapeutic agent, paravertebral facet (zygapophyseal) joint with image guidance (fluoroscopy or CT), lumbar or sacral; single level.
1–10 of 12
1/2
Applicable Diagnosis CodesICD-10
M47.812
Spondylosis without myelopathy or radiculopathy, cervical region.
M47.813
Spondylosis without myelopathy or radiculopathy, cervicothoracic region.
M47.814
Spondylosis without myelopathy or radiculopathy, thoracic region.
M47.815
Spondylosis without myelopathy or radiculopathy, thoracolumbar region.
M47.816
Spondylosis without myelopathy or radiculopathy, lumbar region.
M47.817
Spondylosis without myelopathy or radiculopathy, lumbosacral region.
M47.819
Spondylosis without myelopathy or radiculopathy, site unspecified.
M47.892
Other spondylosis, cervical region.
M47.893
Other spondylosis, cervicothoracic region.
M47.894
Other spondylosis, thoracic region.
1–10 of 15
1/2
inv-16: Diagnostic block positive threshold
Primary threshold>= 50% pain relief for at least the expected minimum duration of the local anesthetic.
Assessment timingRelief must be measured for at least the expected minimum duration corresponding to the local anesthetic used.
Use caseThis ≥50% threshold is used to consider a diagnostic facet joint injection or medial branch block positive in many contexts, particularly for initial diagnostic blocks.
DocumentationPercent pain relief and onset/duration consistent with agent used should be documented in the medical record.
inv-17: Diagnostic block positive response threshold — ≥ 80% (commonly used for confirmatory lumbar blocks); ≥ 50% used/referenced for some cervical guidelines
Provider Requirements, Prior Authorization, and Documentation
Prior Authorization
Prior Authorization Required and Benefit Verification
Prior authorization is required for facet joint and medial branch block injections billed with the applicable CPT/HCPCS codes for UnitedHealthcare Commercial and Individual Exchange plans. Prior authorization requests must document diagnostic strategy, conservative therapy trials, and the member-specific benefit verification. In all cases, review the member-specific benefit plan and any applicable federal or state mandates before proceeding; the member-specific plan governs in the event of a conflict.
Prior authorization required for diagnostic and confirmatory facet/medial branch injections
Verify member-specific benefits and prior authorization requirements before scheduling
Prior Authorization
Prior authorization: diagnostic confirmation and conservative measures
Prior authorization should confirm the diagnostic strategy (single vs dual/confirmatory blocks), documentation of percent pain relief, concordant onset and duration with the local anesthetic used, and that radiofrequency ablation is being considered when applicable. A second confirmatory block is indicated only when the initial block produced ≥ 80% relief of the index pain and the onset and duration of relief are consistent with the agent used. Dual blocks at the same locations on two separate occasions are generally required to confirm facet-mediated pain due to false-positive rates of single injections.
Imaging and Procedural Guidance
Billing Rule
Use fluoroscopy or CT guidance; ultrasound guidance not covered
Facet joint and medial branch injections should be performed using fluoroscopy or CT guidance; ultrasound-guided facet injections are not supported by evidence and are listed as not covered.
Policy preference: fluoroscopy or CT guidance for facet/medial branch injections.
Ultrasound-guided injections are considered not medically necessary per the policy.
Billing Rule
Obtain CT/MRI for upper cervical injections; follow imaging and volume guidance for cervical blocks
For upper cervical (atlanto-occipital/atlanto-axial) injections, obtain preprocedural CT or MRI to guide needle trajectory; for cervical medial branch blocks, use fluoroscopy or ultrasound per guidance and adhere to cervical volume limits.
Cervical medial branch block volumes should be ≤ 0.3 mL; cervical interarticular total volume should not exceed 1 mL.
Definitions and Key Terms
inv-31: Diagnostic Facet Joint Injection / Medial Branch Block — Injection of local anesthetic (with/without corticosteroid) into the facet joint or medial branch nerve with imaging guidance; positive w...
DefinitionInjection of local anesthetic (with or without corticosteroid) into the facet joint capsule or along the medial branch (facet nerve) with imaging guidance to diagnose (and sometimes treat) facet-mediated pain.
Positive diagnostic criteriaConsidered positive when there is at least 50% relief of pain for at least the expected minimum duration of the local anesthetic used.
Imaging guidanceProcedures should be performed with appropriate imaging guidance (fluoroscopy or CT preferred); cervical medial branch blocks may use fluoroscopy or ultrasound per guidance, though ultrasound guidance overall is not supported when used broadly.
Clinical prerequisitesIndicated after a documented minimum trial of conservative care (minimum 4 weeks) with pain ≥3/10 and when radiofrequency denervation/ablation is being considered.
inv-32: Conservative Therapy — Combination of medication (e.g., NSAIDs, analgesics) plus physical therapy, spinal manipulation, CBT, or other tailored interventions.
Services Not Covered
Therapeutic facet joint and medial branch injections for chronic spinal pain at all levels are listed as not covered because evidence does not demonstrate consistent therapeutic benefit and several guideline groups advise against routine or repeated therapeutic injections.
Ultrasound-guided facet joint/medial branch injections are explicitly listed among not covered services due to operator-dependent accuracy concerns and lack of evidence demonstrating equivalent outcomes to fluoroscopy or CT guidance. Additionally, medial branch blocks with local anesthetic volumes exceeding 0.5 mL are considered unproven and not covered.
Therapeutic facet joint and medial branch injections remain not covered when used as routine therapy for acute or subacute low back pain or radicular syndromes, aligning with ACOEM and other society recommendations that oppose these uses.
Coverage exclusions also apply to therapeutic injections performed when radiofrequency ablation is not considered as an alternative treatment option at the requested level(s), reflecting guidance that therapeutic injections should not substitute for definitive procedures without evidence of benefit.
Therapeutic medial branch blocks continue to be categorized as not covered for long-term therapeutic intent due to lack of supportive evidence; NASS notes the paucity of controlled trials and limited literature, especially for thoracic procedures.
Intra-articular steroid injections selected on the basis of a single diagnostic injection with 50% relief have shown no clinically meaningful improvement at 6 months in some analyses, further supporting a not-covered stance for routine therapeutic use.
Facet joint/medial branch therapeutic injections performed under ultrasound guidance are listed as not covered because available evidence does not establish their equivalence to fluoroscopy/CT guidance and studies report operator-dependent accuracy concerns and higher rates of incorrect needle placement when compared with fluoroscopy/CT in some analyses.
Background and Evidence Summary
Facet joint injections and medial branch blocks are commonly used to diagnose pain arising from the zygapophyseal (facet) joints; medial branch blocks target the medial branch nerves that innervate those joints. Diagnostic blocks are intended to identify facet-mediated pain and guide selection of patients for definitive therapies such as radiofrequency denervation.
A diagnostic block is generally considered positive when it produces ≥ 50% pain relief for at least the expected duration of the local anesthetic; because single diagnostic injections have a high false-positive rate, many societies recommend dual (confirmatory) medial branch blocks performed on two separate occasions with a higher threshold (commonly ≥ 80% relief) for confirmatory testing to improve diagnostic specificity.
Policy Revision History
2026-05-01revisionLatest
Updated Description of Services, Clinical Evidence, and References; archived previous policy version 2026T0004UU.
Policy Summary
PayerUnitedHealthcare
PolicyFacet Joint and Medial Branch Block Injections for Spinal Pain
Policy CodePolicy 2026T0004VV
Change TypeRevised clinical evidence, description of services, and references
Effective DateMay 1, 2026
Next Review Date
Key ActionObtain prior authorization and document diagnostic strategy, percent pain relief, and prior conservative therapy before requesting coverage.
Use low injectate volumes to improve specificity and limit spread: lumbar medial branch blocks < 0.5 mL total; lumbar interarticular injections < 1.5 mL; cervical medial branch blocks volumes <= 0.3 mL and cervical interarticular total volume <= 1 mL.
volumes as stated
Aimed to reduce spread/false-positive results and prevent capsular rupture
Avoid routine use of therapeutic facet injections for acute/subacute low back pain, radicular pain syndromes, or routine chronic nonspecific axial pain; consider therapeutic injections only in select patients (e.g., those at high risk from radiofrequency ablation or when other options are limited) and avoid routine steroid use per some guidelines.
select patient scenarios only
ACOEM/ASRA/VA‑DoD guidance discourages routine use
< 80% relief
Based on society guidance
At least 6 weeks to 3 months depending on guidance and spinal level
ASRA/ASIPP recommend 6 weeks to 3 months of conservative therapy before interventions
inv-41: Frequency limits — No explicit numeric frequency limits provided in this excerpt; societies recommend conservative trial periods and diagnostic confirmation rather than specific repeat frequency limits.
Numeric frequency limitsNo explicit numeric repeat-frequency limits are specified in this policy excerpt.
Society recommendationsSocieties recommend conservative trial periods (e.g., 6 weeks to 3 months) and using diagnostic confirmation (single vs dual strategy) rather than routine repeat injections.
Second diagnostic block guidanceA second (confirmatory) diagnostic block may be performed on a separate occasion when indicated (dual blocks).
Therapeutic injections after diagnosticsAfter two diagnostic injections at the same level/side, further injections for therapeutic purposes are considered unproven and not medically necessary per the policy.
inv-42: medial branch diagnostic blocks — Dual diagnostic blocks on two separate occasions (required for diagnosis)
RequirementDual diagnostic medial branch blocks performed at the same location(s) on two separate occasions are necessary to confirm the diagnosis due to high false-positive rates of single injections.
Confirmatory thresholdConfirmatory (second) block is indicated only if the first injection produces ≥ 80% relief and onset/duration are consistent with the agent used.
Alternate scenarioA second injection may be performed at a different/additional level if initial relief was < 80% and a different joint is suspected.
RationaleDual blocks reduce false-positive diagnosis and improve selection for radiofrequency denervation/ablation per guideline recommendations.
Confirmatory threshold
≥ 80% pain relief is required for a confirmatory (second) medial branch diagnostic block (commonly used for lumbar blocks).
Cervical guidanceSome cervical guidelines reference ≥ 50% as a positive response for certain cervical prognostic blocks; practice varies by society guidance.
When to repeat/redirectIf initial relief is < 80%, a second injection may target a different level if clinical suspicion indicates another joint.
PurposeAn ≥80% confirmatory threshold seeks high specificity given high false-positive rates of single blocks.
Document whether single or dual (confirmatory) diagnostic blocks are being performed
If a confirmatory block is requested, include documentation that the initial block produced ≥ 80% pain relief and that onset/duration matched the anesthetic used
If pain relief from the initial block was < 80%, documentation supporting targeting of an additional level is required
Prior Authorization
Conservative therapy before interventions
Documented trial and failure or contraindication of conservative therapy is required prior to diagnostic prognostic blocks in most cases. Conservative therapy may include pharmacologic management, physical therapy/exercise, activity modification, integrative modalities (e.g., acupuncture, spinal manipulation), weight loss, and sleep hygiene. Timing recommendations from specialty guidance include at least 4 weeks of conservative care for lumbar indications and at least a 6-week trial (or up to 3 months individualized) for cervical/neck pain prior to blocks, unless clinically contraindicated.
Minimum 4 weeks of conservative care documented for lumbar indications (unless contraindicated)
For cervical/neck pain, document at least a 6-week trial of conservative therapy or individualized plan (up to 3 months as indicated)
Concomitant use of conservative measures is expected to accompany prognostic blocks
Note
Verify benefit and authorization
Before submitting a request, verify the member-specific benefit plan document and any applicable federal or state mandates. In the event of conflict between this policy and the member-specific benefit plan, the member-specific plan governs. This policy may be applied to Medicare Advantage in the absence of an NCD/LCD, and UnitedHealthcare may use third-party tools (e.g., InterQual) to assist in benefit administration.
Reference the member-specific benefit plan document for coverage determinations
Check for applicable federal or state mandates prior to authorization decision
Medicare Advantage: apply only in absence of NCD/LCD guidance and consistent with CMS rules
Documentation Required
Required documentation
Medical records and procedural documentation supporting the medical necessity determination must be submitted with prior authorization requests and retained in the medical record. UnitedHealthcare may require medical record review to assess whether clinical criteria are met; submission does not guarantee coverage.
Include complete medical records documenting conservative care trials, physical exam findings with facet-loading maneuvers, and imaging studies that exclude other causes of pain
Medical records used for reviews do not guarantee coverage; the member-specific plan governs
Documentation Required
Required procedural and clinical documentation
Procedural and clinical documentation must include specific details of diagnostic blocks: percent pain relief, timing of onset and duration of relief consistent with the local anesthetic used, the anatomic level(s) and laterality, technique and guidance modality, injectate type and total volume, and whether radiofrequency denervation is being considered. For cervical medial branch and interarticular injections follow published volume limits to enhance specificity.
Document percent pain relief (e.g., ≥ 80% for confirmatory block; ≥ 50% considered positive for some cervical blocks per specialty guidance)
Document onset and minimum duration of relief consistent with the anesthetic used
If requesting subsequent therapeutic injections, document rationale and relation to prior diagnostic blocks (therapeutic injections after two diagnostic blocks at same level/side are considered unproven)
Denial Risk
Denial triggers for unproven indications
Requests for therapeutic facet joint or medial branch blocks after diagnostic injections (including more than two injections at the same level/side) are considered unproven and not medically necessary unless documentation shows radiofrequency ablation is not an option and clear supporting evidence is provided. Injection volumes exceeding recommended maxima or procedures performed under ultrasound guidance (when not supported by criteria) may be denied.
Therapeutic facet/medial branch injections after two diagnostic injections at same level/side are not medically necessary
Do not exceed recommended injectate volumes for medial branch or interarticular injections
Requests for procedures performed under ultrasound guidance when policy specifies other guidance may be denied
Note
Plan and regulatory compliance
Coverage decisions are subject to the member-specific benefit plan terms and applicable laws. FDA approval alone is not a basis for coverage. This Medical Policy is informational and does not constitute medical advice; UnitedHealthcare reserves the right to modify policies and may apply third-party criteria to assist in administration.
Member-specific benefit plan governs in case of conflict
FDA approval by itself does not establish coverage
Policy may be modified and third-party tools may be used to administer benefits
Preprocedural advanced imaging (CT or MRI) is recommended before atlanto-occipital and atlanto-axial joint injections.
Note
Regulatory note: devices and imaging may be FDA regulated (informational only)
Devices, drugs, and imaging used during procedures may be regulated by the U.S. Food and Drug Administration; this information is provided for informational purposes and FDA status alone does not determine coverage.
Consult FDA resources for device/drug regulation details; coverage is determined by plan terms.
DefinitionConservative therapy consists of a combination of medication (e.g., NSAIDs, analgesics) plus physical therapy, spinal manipulation, cognitive behavioral therapy, or other tailored interventions based on individual presentation.
Typical componentsMay include NSAIDs, antidepressants, exercise programs, heat/cold therapy, massage, acupuncture, spinal manipulation, nutrition, weight loss, and sleep hygiene.
Recommended duration before interventionsRecommended trial duration varies by guidance: minimum 4 weeks for initial diagnostic injection; many societies recommend 6 weeks to 3 months prior to prognostic/therapeutic blocks.
Documentation requirementMedical records should document prior conservative care and persistent pain (≥3/10) before proceeding with diagnostic injections.
inv-33: Dual (confirmatory) diagnostic medial branch block — Two injections at the same target on separate occasions with an initial high-magnitude pain relief (often ≥ 80%) and concordant onset/dur...
DefinitionDual (confirmatory) diagnostic medial branch blocks are two injections at the same target performed on separate occasions with concordant onset/duration and a high-magnitude pain relief (often ≥ 80%) to confirm facet-mediated pain.
TimingPerformed on two separate occasions; the second is confirmatory only if the first produced ≥ 80% relief consistent with the anesthetic's expected duration.
RationaleUsed because single diagnostic anesthetic injections have an unacceptably high false-positive rate; dual blocks increase diagnostic specificity for selecting patients for radiofrequency ablation.
Alternate approachIf initial relief is < 80%, the second injection may target a different level if clinical suspicion indicates another joint.
Role before proceduresThese measures should be trialed and documented prior to prognostic or therapeutic facet interventions; societies recommend at least 6 weeks to 3 months in many scenarios.
Personalized approachDuration and selection of conservative therapies may be individualized based on patient presentation and guideline recommendations.
inv-35: Diagnostic medial branch blocks (dual blocks) — Two anesthetic blocks performed at the same location on separate occasions to confirm facet joint pain due to high false-positive rates o...
DefinitionDiagnostic medial branch blocks (dual blocks) are two anesthetic blocks performed at the same location on separate occasions to confirm facet joint pain due to high false-positive rates of single injections.
Confirmatory criteriaSecond confirmatory injection is indicated only if first produced ≥ 80% relief with onset/duration consistent with the agent used.
Clinical useUsed to select patients for radiofrequency denervation/ablation and to avoid inappropriate therapeutic injections when diagnosis is uncertain.
Policy implicationTherapeutic injections after two diagnostic blocks at the same level/side are considered therapeutic and are listed as unproven/not medically necessary in many cases.
inv-36: Therapeutic medial branch blocks — Blocks performed similarly to diagnostic medial branch blocks intended for long-term pain management, though current evidence does not su...
DefinitionTherapeutic medial branch blocks are performed similarly to diagnostic medial branch blocks and are intended for long-term pain management, but current evidence does not support their use as a therapeutic intervention.
Evidence stanceEvidence for therapeutic benefit is limited and of low/very low quality; systematic reviews and guideline statements caution routine therapeutic use.
Policy statusTherapeutic medial branch blocks and therapeutic facet joint injections are considered unproven and not medically necessary in many contexts per this policy.
Clinical considerationConsider alternative evidence-based interventions (e.g., radiofrequency neurotomy where appropriate) and document diagnostic confirmation before any therapeutic injection.
Providers should use fluoroscopy or CT guidance as the preferred imaging modalities for these procedures; ultrasound-guided techniques remain nonstandard and excluded from coverage.
Routine therapeutic facet joint injections for acute/subacute low back pain, radicular syndromes, or chronic nonspecific axial pain are not covered in accordance with ACOEM, ASRA, and VA/DoD guidance that discourages these indications and the routine use of intra-articular corticosteroids for many patients.
When repeat intra-articular injections are requested for patients without lasting functional improvement, society guidance and evidence reviews moderate their use and support noncoverage for routine repeat therapeutic injections.
Therapeutic facet joint and medial branch injections for chronic spinal pain at all levels are not covered because multiple systematic reviews and guideline bodies identify insufficient, low-quality, and inconsistent evidence for durable benefit.
Coverage exclusion applies to therapeutic medial branch blocks as an evidence-supported long-term therapeutic intervention and to intra-articular steroid injections when used routinely without appropriate diagnostic confirmation.
Therapeutic facet joint and medial branch injections under ultrasound guidance are not covered due to limited supporting evidence, concerns about operator dependence, and data suggesting higher rates of incorrect needle placement compared with fluoroscopy or CT in some studies.
Providers should document use of fluoroscopy or CT guidance when requesting coverage for diagnostic or therapeutic facet procedures.